Gen-Probe Broadens Intellectual Property Portfolio For Automated Nucleic Acid Testing

The US and European patent authorities have granted seven additional patents to Gen-Probe. It extend the company’s intellectual property estate related to automated instrument systems for nucleic acid testing (NAT).

The newly granted patents relate to automated sample preparation and target nucleic acid amplification, as well as closed-tube sampling. The patents complement an extensive portfolio of 65 patents previously granted to Gen-Probe, that relate to automated instrument systems for nucleic acid testing.

Bill Bowen, senior vice president and general counsel of Gen-Probe, said: These important new patents extend an already strong intellectual property estate surrounding automated instrumentation for molecular diagnostics, and further acknowledge the pioneering work our R&D team has done on behalf of our customers.